Export financials
Trillium Therapeutics Inc. (TRIL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Trillium Therapeutics Inc. Balance Sheet 2020-2011 | TRIL
Brief balance sheet overview of Trillium Therapeutics Inc.
The comparison uses five available annual reports from the 2016–2020 interval.
Total assets increased by +500.5%, from $50.1 million to $300.8 million. A CAGR near 56.5% points to substantial expansion.
Liabilities grew more slowly than assets: +243.7% versus +500.5%. Expansion relied more on equity, improving funding quality.
Net debt moved below zero to -$246.8 million, reflecting surplus cash over debt.
The balance sheet carries negative retained earnings of -$249.4 million. The figure may result from accumulated losses or an active capital return policy.
Overall assessment
Trillium Therapeutics Inc.'s financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Trillium Therapeutics Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-247 M | -14.6 M | -15.3 M | -21.3 M | -37.8 M | -86.5 M | -25.9 M | -30.2 M | -1.38 M | -2.64 M |
Long Term Debt |
- | - | - | 73.7 K | 143 K | 270 K | 280 K | 321 K | - | - |
Total Non Current Liabilities |
557 K | 12 M | 371 K | 982 K | 1.95 M | 680 K | 350 K | 419 K | - | - |
Total Current Liabilities |
21.4 M | 13.5 M | 9.82 M | 10.9 M | 4.45 M | 3.56 M | 3.53 M | 688 K | 186 K | 347 K |
Total Liabilities |
22 M | 25.6 M | 10.2 M | 11.9 M | 6.39 M | 4.24 M | 3.88 M | 1.11 M | 186 K | 347 K |
Retained Earnings |
-249 M | -191 M | -149 M | -102 M | -67.8 M | -58.4 M | -41.3 M | -35.4 M | -33.6 M | -31.7 M |
Total Assets |
301 M | 25.4 M | 40.8 M | 71 M | 50.1 M | 90 M | 28.2 M | 33 M | 1.58 M | 2.71 M |
Annual performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Trillium Therapeutics Inc., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Certara
CERT
|
$ 10.56 | -1.12 % | $ 1.69 B | ||
|
Intec Pharma Ltd
NTEC
|
- | -12.45 % | $ 17.7 M | ||
|
Anika Therapeutics
ANIK
|
$ 13.26 | -0.15 % | $ 190 M | ||
|
Aprea Therapeutics
APRE
|
$ 0.23 | -52.81 % | $ 1.5 M | ||
|
Galectin Therapeutics
GALT
|
$ 2.68 | -4.63 % | $ 171 M | ||
|
Processa Pharmaceuticals
PCSA
|
$ 1.59 | -5.92 % | $ 2.08 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
$ 63.61 | -2.11 % | $ 6.61 B | ||
|
Progenity, Inc.
PROG
|
- | -3.47 % | $ 164 M | ||
|
Genprex
GNPX
|
$ 1.46 | -12.87 % | $ 1.36 M | ||
|
Strongbridge Biopharma plc
SBBP
|
- | 1.52 % | $ 136 M | ||
|
Nektar Therapeutics
NKTR
|
$ 30.23 | -7.1 % | $ 510 M | ||
|
Innate Pharma S.A.
IPHA
|
$ 0.87 | -7.57 % | $ 77.9 M | ||
|
Seneca Biopharma, Inc.
SNCA
|
- | -1.19 % | $ 28.7 M | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 60.42 | -1.64 % | $ 11.6 B | ||
|
Matinas BioPharma Holdings
MTNB
|
$ 0.75 | -9.23 % | $ 4.11 M | ||
|
Enanta Pharmaceuticals
ENTA
|
$ 7.6 | -4.82 % | $ 220 M | ||
|
Milestone Pharmaceuticals
MIST
|
$ 0.38 | -5.66 % | $ 40.4 M | ||
|
Lipocine
LPCN
|
$ 1.47 | -2.33 % | $ 8.01 M | ||
|
Seres Therapeutics
MCRB
|
$ 1.25 | -6.02 % | $ 11.1 M | ||
|
Oramed Pharmaceuticals
ORMP
|
$ 3.58 | -2.98 % | $ 148 M | ||
|
Madrigal Pharmaceuticals
MDGL
|
$ 378.19 | -4.68 % | $ 8.48 B | ||
|
CEL-SCI Corporation
CVM
|
$ 1.2 | -18.37 % | $ 9.62 M | ||
|
Inventiva S.A.
IVA
|
$ 3.14 | -9.13 % | $ 188 M | ||
|
MeiraGTx Holdings plc
MGTX
|
$ 7.98 | -1.97 % | $ 642 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
$ 39.21 | 1.76 % | $ 44.9 B | ||
|
Eton Pharmaceuticals
ETON
|
$ 60.77 | -0.96 % | $ 1.64 B | ||
|
IDEAYA Biosciences
IDYA
|
$ 25.52 | -2.48 % | $ 2.26 B | ||
|
Protalix BioTherapeutics
PLX
|
$ 2.89 | -5.56 % | $ 227 M | ||
|
Lantern Pharma
LTRN
|
$ 0.25 | -13.67 % | $ 2.72 M | ||
|
Foghorn Therapeutics
FHTX
|
$ 1.71 | -3.93 % | $ 108 M | ||
|
Ocugen
OCGN
|
$ 0.77 | 4.74 % | $ 241 M | ||
|
Oncolytics Biotech
ONCY
|
$ 0.35 | -10.37 % | $ 33.6 M | ||
|
Minerva Neurosciences
NERV
|
$ 2.03 | -4.25 % | $ 17.2 M | ||
|
Neurocrine Biosciences
NBIX
|
$ 150.5 | -3.89 % | $ 15 B | ||
|
Nanobiotix S.A.
NBTX
|
$ 26.12 | -1.7 % | $ 1.25 T | ||
|
Prothena Corporation plc
PRTA
|
$ 8.12 | -3.33 % | $ 437 M | ||
|
Mereo BioPharma Group plc
MREO
|
$ 0.26 | -5.45 % | $ 207 M | ||
|
Maravai LifeSciences Holdings
MRVI
|
$ 6.99 | -2.85 % | $ 1.01 B | ||
|
Lexicon Pharmaceuticals
LXRX
|
$ 1.53 | -8.68 % | $ 555 M | ||
|
Moleculin Biotech
MBRX
|
$ 7.73 | -2.59 % | $ 9.16 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
$ 21.79 | 1.66 % | $ 34.4 B | ||
|
Nurix Therapeutics
NRIX
|
$ 12.88 | -5.29 % | $ 1.12 B | ||
|
Nkarta
NKTX
|
$ 1.14 | 1.34 % | $ 84.3 M | ||
|
MacroGenics
MGNX
|
$ 1.97 | -0.76 % | $ 124 M | ||
|
Protagonist Therapeutics
PTGX
|
$ 121.72 | -2.2 % | $ 7.74 B | ||
|
Novo Nordisk A/S
NVO
|
$ 37.8 | -2.82 % | $ 168 B | ||
|
Marker Therapeutics
MRKR
|
$ 1.1 | -17.05 % | $ 16.8 M | ||
|
Arcus Biosciences
RCUS
|
$ 15.62 | -1.01 % | $ 1.68 B | ||
|
Replimune Group
REPL
|
$ 19.07 | -0.83 % | $ 1.77 B | ||
|
NextCure
NXTC
|
$ 6.62 | -2.43 % | $ 35.2 M |